Keros Therapeutics (KROS) Earnings Date, Estimates & Call Transcripts $17.03 +0.11 (+0.65%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Keros Therapeutics Latest Earnings SummaryActual EPS (Nov. 6) -$1.41 Missed By -$0.13 Consensus EPS (Nov. 6) -$1.28 Keros Therapeutics posted Q3 2024 earnings on November 6, 2024, reporting an EPS of -$1.41, which missed analysts' consensus estimates of -$1.28 by $0.13. Quarterly revenue rose 4750.0% year-over-year to $0.39 million. With a trailing EPS of -$5.21, Keros Therapeutics' earnings are expected to decrease next year, from ($5.26) to ($5.56) per share. Get Keros Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Keros Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataKROS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.KROS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Keros Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244-$1.34-$1.22-$1.26Q2 20244-$1.40-$1.15-$1.24Q3 20244-$1.47-$1.22-$1.32Q4 20244-$1.48-$1.30-$1.39FY 202416-$5.69-$4.89-$5.20Q1 20253-$1.51-$1.23-$1.38Q2 20253-$1.57-$1.04-$1.33Q3 20253-$1.54-$0.79-$1.23Q4 20253-$1.59-$0.58-$1.17FY 202512($6.21)($3.64)($5.12) Keros Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/6/2024Q3 2024-$1.28-$1.41 -$0.13-$1.41-$0.39M8/7/2024Q2 2024-$1.23-$1.25 -$0.02-$1.25-$0.04M5/8/2024Q1 2024-$1.33-$1.21+$0.12-$1.21-$0.08M3/1/2024Q4 2023-$1.37-$1.34+$0.03-$1.34-$0.14M11/6/2023Q3 2023-$1.35-$1.33+$0.02-$1.33-$0.01M8/7/2023Q2 2023-$1.34-$1.27+$0.07-$1.27$0.22M-URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now5/4/2023Q1 2023-$1.14-$1.26 -$0.12-$1.26$0.22M-3/3/2023Q4 2022-$1.12-$1.09+$0.03-$1.09-- Keros Therapeutics Earnings - Frequently Asked Questions When did Keros Therapeutics announce their last quarterly earnings? Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earning data on Wednesday, November 6, 2024. Learn more on KROS's earnings history. Did Keros Therapeutics beat their earnings estimates last quarter? In the previous quarter, Keros Therapeutics (NASDAQ:KROS) missed the analysts' consensus estimate of ($1.28) by $0.13 with a reported earnings per share (EPS) of ($1.41). Learn more on analysts' earnings estimate vs. KROS's actual earnings. How much revenue does Keros Therapeutics generate each year? Keros Therapeutics (NASDAQ:KROS) has a recorded annual revenue of $651,000.00. How much profit does Keros Therapeutics generate each year? Keros Therapeutics (NASDAQ:KROS) has a recorded net income of -$152.99 million. KROS has generated -$5.21 earnings per share over the last four quarters. What is Keros Therapeutics's EPS forecast for next year? Keros Therapeutics's earnings are expected to decrease from ($5.26) per share to ($5.56) per share in the next year. More Earnings Resources from MarketBeat Related Companies MRUS Earnings ACAD Earnings TWST Earnings VCEL Earnings MOR Earnings SWTX Earnings KYMR Earnings ZLAB Earnings VERA Earnings BHC Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. This page (NASDAQ:KROS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
